BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

• Published in: Journal of clinical pharmacology Vol. 57; no. 11; p. 1460
• Main Authors: Sakamoto, Kei, Matsuki, Shunji, Matsuguma, Kyoko, Yoshihara, Tatsuya, Uchida, Naoki, Azuma, Fumihiko, Russell, Muir, Hughes, Glen, Haeberlein, Samantha Budd, Alexander, Robert C, Eketjäll, Susanna, Kugler, Alan R
• Format: Journal Article
• Language: English
• Published: England 01.11.2017
• Subjects: Adult; Aged; Alzheimer Disease - drug therapy; Amyloid beta-Peptides - metabolism; Amyloid beta-Protein Precursor - metabolism; Amyloid Precursor Protein Secretases - antagonists & inhibitors; Amyloid Precursor Protein Secretases - metabolism; Asian Continental Ancestry Group; Aspartic Acid Endopeptidases - antagonists & inhibitors; Brain - metabolism; Cerebrospinal Fluid - metabolism; Double-Blind Method; Female; Half-Life; Healthy Volunteers; Humans; Imidazoles - therapeutic use; Male; Middle Aged; Peptide Fragments - metabolism; Plasma - metabolism; Spiro Compounds - therapeutic use; Young Adult; Alzheimer disease; amyloid-β peptides; lanabecestat, AZD3293; clinical trials; BACE1 protein-human; Japanese; cerebrospinal fluid proteins

Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β-secretase 1 in clinical development for the treatment of Alzheimer disease. In this first Japanese clinical study for an Alzheimer disease intervention to include cerebrospinal fluid (CSF) sampling in Japanese elderly...